|
|
Pre-irradiation chemotherapy for newly diagnosed
high grade astrocytoma
Mathieu NT, Genet D, Labrousse F, Bouillet P, Denes SL, Martin J, Labourey
JL, Venat L, Clavere P, Moreau JJ
Department of Medical Oncology and Radiotherapy, CHU Dupuytren, 2
avenue Martin Luther King, 87042 Limoges Cedex, France. oncologie@chu-limoges.fr
The purpose of this work was to determine the response rate and toxicity of a
combination of Carmustine and Cisplatin administered before radiation in
patients with newly diagnosed high grade astrocytoma.
A good response rate has been published with this association in primary
cerebral high grade tumor.
This protocol was administered in a homogeneous population of 37 adult patients
with measurable tumor on magnetic resonance imaging (MRI) or CT scan.
After biopsy or subtotal resection, the patients received BCNU 40 mg/m2/d and
CODP 40 mg/m2/d, for 3 days every 28 days for 3 cycles.
Evaluation was performed before each cycle.
Radiation therapy began 4 weeks after completing the chemotherapy or immediately
if there was evidence of tumor progression on chemotherapy.
Seven out of 37 (19%) demonstrated tumor regression with a median duration to
progression of 11 months.
Median survival was 6 months.
Myelosuppression was the predominant but manageable toxicity.
This work indicated that the first chemotherapy protocol gave poor results in a
homogeneous group of patients, with bad prognosis.
PMID: 15154655 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15154655
|
